Hançerli Yusuf, Kaplan Mustafa, Tanoğlu Alpaslan, Yeşilbaş Soner, Küçükodacı Zafer, Yıldırım Muhammet, Narlı Gizem, Sakin Yusuf Serdar
Department of Internal Medicine, Sultan Abdulhamit Training and Research Hospital, İstanbul, Turkey.
Turk J Gastroenterol. 2017 Nov;28(6):485-491. doi: 10.5152/tjg.2017.16738. Epub 2017 Oct 25.
BACKGROUND/AIMS: Acute pancreatitis (AP) is a disease that can cause local and systemic complications that may have high morbidity and mortality. Currently, there is not any specific treatment for AP. In this study, we created an experimental model of AP in rats, and we aimed to demonstrate the histological effectiveness of tocilizumab treatment that antagonizes interleukin-6 (IL-6), one of the key cytokines in the development of AP.
Forty-eight rats were divided into six groups for this study. AP model was created by subcutaneous injections of cerulein (20 μg/kg) four times at 1-h intervals. Tocilizumab 4 mg/kg was administered to one of the treatment groups and 8 mg/kg to the other treatment group intraperitoneally. The effects of tocilizumab were revealed by examining pancreatic tissue of the rats histopathologically according to the Schonberg scoring system.
A comparison between tocilizumab treatment group and AP control group provides statistically significant improvement in AP (p<0.0001). Furthermore, the dose of 8 mg/kg is shown to be more effective than 4 mg/kg (p=0.004).
Our study points out that tocilizumab may be an effective agent for pancreatitis treatment.
背景/目的：急性胰腺炎（AP）是一种可导致局部和全身并发症的疾病，这些并发症可能具有较高的发病率和死亡率。目前，尚无针对AP的特异性治疗方法。在本研究中，我们建立了大鼠AP实验模型，旨在证明托珠单抗治疗的组织学有效性，托珠单抗可拮抗白细胞介素-6（IL-6），IL-6是AP发生发展过程中的关键细胞因子之一。
本研究将48只大鼠分为6组。通过每隔1小时皮下注射4次雨蛙素（20μg/kg）建立AP模型。其中一个治疗组腹腔注射4mg/kg托珠单抗，另一个治疗组腹腔注射8mg/kg托珠单抗。根据舍恩贝格评分系统对大鼠胰腺组织进行组织病理学检查，以揭示托珠单抗的作用效果。
托珠单抗治疗组与AP对照组相比，AP有统计学意义的改善（p<0.0001）。此外，8mg/kg剂量组比4mg/kg剂量组更有效（p=0.004）。
我们的研究指出，托珠单抗可能是一种有效的胰腺炎治疗药物。
